About Centurion BioPharma Corporation

Centurion BioPharma Corporation

Fighting cancer with cutting-edge science

  • Private company with focus on preclinical research in oncology

  • Discovered and owns full rights to LADR™ platform

Would you like to receive an email when there is news about Centurion?
(* indicates required fields)

Management


  • Eric Curtis
    CEO and President

    Mr. Curtis brings 25 years of life science leadership experience, specializing in oncology and orphan diseases. He was instrumental in the US and global development and commercialization of Votrient®, Doxil®, Velcade®, Benlysta®, Tykerb® and Adempas®.

    Prior to joining Centurion, Mr. Curtis served in senior leadership roles as President and COO of CytRx Corporation, President, U.S. Commercial at Aegerion Pharmaceuticals, VP and GM – Rare Disease Business Unit at Bayer Healthcare, VP and global commercial leader at GlaxoSmithKline, and roles of increasing responsibility at Centocor/J&J.

  • John Caloz
    Chief Financial Officer

    Mr. Caloz has an accomplished history of providing senior financial leadership in the life sciences sector, including as Chief Financial Officer of Occulogix, Inc, a NASDAQ listed, a medical therapy company. Prior to that, Mr. Caloz served as Chief Financial Officer of IRIS International Inc., a Chatsworth, CA based medical device manufacturer. He served as Chief Financial Officer of San Francisco-based Synarc, Inc., a medical imaging company, and from 1993 to 1999 he was Senior Vice President, Finance and Chief Financial Officer of Phoenix International Life Sciences Inc. of Montreal, Canada, which was acquired by MDS Inc. in 1999. Mr. Caloz was a partner at Rooney, Greig, Whitrod, Filion & Associates of Saint Laurent, Quebec, Canada, a firm of Chartered Accountants specializing in research and development and high tech companies, from 1983 to 1993. Mr. Caloz, a Chartered Accountant, holds a degree in Accounting from York University, Toronto, Canada.